

## PRESS RELEASE

### AnaCardio's AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

**STOCKHOLM, Sweden – March 26, 2026** – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have been selected for presentation in the Late-Breaking Science program at the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) 2026 Congress in Barcelona.

Late-Breaking Science presentations are reserved for studies of high scientific and clinical importance, highlighting impactful advances in cardiovascular medicine.

The presentation, titled *“Randomized, double-blind, placebo-controlled, safety, tolerability, PK, PD and exploratory efficacy phase 1b/2a trial with AC01 in patients with HFrEF”* will be held by Professor Lars Lund of Karolinska University Hospital on Saturday, May 10, 15.30 CET.

GOAL-HF1 is the first clinical study in patients with the novel oral calcium-sensitising inotrope AC01, a ghrelin receptor agonist, in HFrEF and consisted of two parts: a sequential dose-escalation over seven days (Phase 1b) followed by a cohort expansion over 28 days (Phase 2a), including 58 patients enrolled at 14 sites in 4 countries in Europe. AC01 demonstrated a favorable safety and tolerability profile, achieved target engagement and exhibited promising signals of improved systolic function. These results justify advancing AC01 to Phase 2b development in HFrEF.

*“We are pleased that the GOAL-HF1 results have been selected for Late-Breaking Science presentation at HFA 2026 Congress,”* said Patrik Strömberg, CEO of AnaCardio. *“Heart failure with reduced ejection fraction remains one of the largest areas of unmet medical need in cardiovascular medicine, with persistently high morbidity and mortality despite broad adoption of guideline-directed medical therapies. We believe AC01’s novel mechanism has the potential to address important gaps in current treatment, and we look forward to sharing these data with the scientific community.”*

#### Presentation Details

- **Event:** Heart Failure Association 2026 Congress
- **Session:** Late-Breaking Science; Advances in heart failure detection and therapy
- **Title:** Randomized, double-blind, placebo-controlled, safety, tolerability, PK, PD and exploratory efficacy phase 1b/2a trial with AC01 in patients with HFrEF
- **Presenter:** Professor Lars Lund, Karolinska University Hospital
- **Date/Time:** Saturday May 10, 15.30 CET

## About the GOAL-HF1 HFrEF study

GOAL-HF1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). All patients had NYHA class II-III heart failure with reduced ejection fraction, an ICD for primary prevention and optimized guideline-directed medical therapy.

- Phase 1b consisted of a multiple-dose escalation in 32 patients across four sequential dose cohorts (0.3–3 mg), each treated orally twice daily for 7 days.
- In Phase 2a, 26 patients were equally randomized into one of three parallel treatment arms and treated twice daily with 1 or 3 mg AC01, or placebo for 28 days.

More information about the study is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT05642507).

## About AnaCardio

AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company's lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. AnaCardio recently completed a successful Phase 1b/2a trial with AC01 that generated proof-of-concept in patients with HFrEF, thus supporting further development of this promising oral, first-in-class drug candidate in patients with advanced heart failure.

Find more information about AnaCardio at [www.anacardio.com](http://www.anacardio.com) and follow us on [LinkedIn](#).

## AnaCardio media contact:

Patrik Strömberg, CEO

Telephone: +46 704 156 159

E-mail: [patrik.stromberg@anacardio.com](mailto:patrik.stromberg@anacardio.com)